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Are	there	big	differences		
among	beta-blockers	in	treating	
essential	hypertension?
evidence-based answer
Yes, a number of beta-blockers are effective 
in lowering blood pressure (strength of 
recommendation [sor]: a, multiple, 
consistent randomized controlled trials 
[rCTs]). Cardioselective beta-blockers do 
not alter lung function studies for patients 
with chronic obstructive pulmonary disease 
(CopD) or reversible airway disease (sor: 
a, meta-analysis of rCTs). 
 propranolol and timolol have greater 
risks of causing fatigue as a side effect 
(sor: a, meta-analysis of rCTs). recent 
meta-analyses have stirred debate on the 
effectiveness of the agents in preventing 
adverse outcomes. The level of evidence 
has reached the point where the practice of 
using beta-blockers as monotherapy should 
be questioned (sor: c, expert opinion).
clinical commentary
Beta-blocker debate may be irrelevant 
when these drugs are taken with other 
antihypertensives
Definitive evidence has demonstrated 
reduced risk of cardiovascular events with 
beta-blockers as a primary antihypertensive 
agent for patients with concurrent coronary 
heart disease. However, using a beta-blocker 
as a primary antihypertensive for patients 
without such compelling indications is now 
considered controversial. in 2006, the uK’s 
National institute for Health and Clinical 
excellence published a clinical guideline for 
hypertension1 in which beta-blockers are no 
longer preferred as a routine initial therapy for 
hypertension and are reserved as alternative 
agents after diuretics, angiotensin-converting 
enzyme (aCe) inhibitors, angiotensin receptor 
blockers (arBs), and calcium channel 
blockers. 
 This recommendation was based on 
results from meta-analyses that suggest beta-
blockers, especially atenolol, may not be as 
cardioprotective as other antihypertensives. 
This has been confirmed by a 2007 Cochrane 
analysis.2 Despite a half-life of only 6 to 
7 hours, atenolol is nearly always dosed 
once daily, while carvedilol and metoprolol 
have half-lives of 6 to 10 and 3 to 7 hours, 
respectively, and are dosed at least twice 
daily. it is possible that the controversy with 
beta-blockers arises because atenolol should 
really be a twice-daily drug. 
 in clinical practice, most patients with 
hypertension need more than one agent 
to attain goal blood pressure values. The 
debate over whether one beta-blocker is 
better or worse may be clinically irrelevant 
when beta-blockers are used in combination 
with another antihypertensive.
Joseph Saseen, PharmD, FCCP, BCPS
university of Colorado Health sciences Center
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z	Evidence	summary
Numerous trials have shown that beta-
blockers lower blood pressure for patients 
with hypertension. No head-to-head tri-
als of beta-blockers have been conducted 
that reveal differences in terms of patient-
oriented outcomes, such as all-cause mor-
tality, in the treatment of hypertension. 
No	effect	on	lung	function,		
but	fatigue	is	a	factor
A Cochrane review on the cardioselective 
beta-blockers atenolol (Tenormin), biso-
prolol (Zebeta), and metoprolol (Lopres-
sor) found that single-dose and multiple-
treatment studies showed no decline in 
lung function among patients with mild 
to moderate reversible airway disease or 
chronic obstructive pulmonary disease.3,4 
The analysis was not able to identify any 
differential effect of these beta-blockers 
with or without intrinsic sympathomimet-
ic activity for patients with lung disease.
That said, beta-blockers do have side 
effects. One meta-analysis found no dif-
ference in the development of depression 
with beta-blocker therapy; however, first-
generation beta-blockers (propranolol 
and timolol) had higher rates of fatigue 
than did the later beta-blockers.5 They re-
ported that the risk of fatigue was only 18 
per 1000 patients (95% confidence inter-
val [CI], 5–30) and the risk for sexual dys-
function was 5 per 1000 patients (95% 
CI, 2–8) for all beta-blockers as a class. 
Importantly, they also stratified side-effect 
findings on the basis of lipophilic vs non-
lipophilic and found no difference in side 
effect frequency.
Adverse	outcomes	data		
give	reason	to	pause
Two recent meta-analyses6,7 on beta- 
blockers have called into question the 
effectiveness of these agents in pre-
venting adverse outcomes in treating 
hypertension. 
The first meta-analysis6 reviewed 4 
studies that compared atenolol with pla-
cebo or no treatment, and 5 that com-
pared atenolol with other antihypertensive 
drugs. They found no outcome differences 
between atenolol and placebo in the 4 
studies, comprising 6825 patients, fol-
lowed for a mean of 4.6 years. There was 
no difference in all-cause mortality (rela-
tive risk [RR]=1.01; 95% CI, 0.89–1.15), 
cardiovascular mortality (RR=0.99; 95% 
CI, 0.83–1.18), or myocardial infarction 
(RR=0.99; 95% CI, 0.83–1.19). The risk 
of stroke appeared to be lower in the aten-
olol than in the placebo group (RR=0.85; 
95% CI, 0.72–1.01). When atenolol was 
compared with other antihypertensives, 
there were no major differences in blood 
pressure lowering between the treatment 
arms. 
The authors found a significantly 
higher mortality (RR=1.13; 95% CI, 
1.02–1.25) with atenolol treatment than 
with other active treatment, in 5 studies 
comprising 17,671 patients who were fol-
lowed up for a mean of 4.6 years. Stroke 
was also more frequent with atenolol in 
comparison with other agents. 
The second meta-analysis7 covered 13 
randomized controlled trials (n=105,951) 
comparing treatment with beta-blockers 
with other antihypertensive drugs. Seven 
studies (n=27,433) were included in a 
comparison of beta-blockers and placebo 
or no treatment. The relative risk of stroke 
was 16% higher for beta-blockers (95% 
CI, 4%–30%) than for other drugs. No 
difference was seen for myocardial infarc-
tion. When the effect of beta-blockers was 
compared with that of placebo or no treat-
ment, the relative risk of stroke was re-
duced by 19% for all beta-blockers (95% 
CI, 7%–29%). There was no difference 
for myocardial infarction or mortality. 
An	age	divide	appears		
with	adverse	events
A subsequent meta-analysis found that 
beta-blocker therapy in younger patients 
(less than 60 years of age) is associated 
with a significant reduction in cardiovas-
cular morbidity and mortality.8 Research-
ers used data from 145,811 participants 
in 21 hypertension trials, beta-blockers 
reduced major cardiovascular outcomes 
A meta-analysis 
found that beta-
blockers reduced 
major cardio- 
vascular outcomes 
in younger— 
but not older— 
patients
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Beta-blockers 
were inferior to 
calcium channel 
blockers, ACE  
inhibitors, and 
ARBs for all-cause 
mortality
in younger patients (risk ratio=0.86; 95% 
CI, 0.74–0.99) but not in older patients 
(risk ratio=0.89; 95% CI, 0.75–1.05). 
In active comparator trials, beta-
blockers demonstrated similar reductions 
in morbidity and mortality to other an-
tihypertensive agents in younger patients 
(risk ratio=0.97; 95% CI, 0.88–1.07) 
but not in older patients (risk ratio=1.06; 
95% CI, 1.01–1.10), with the excess risk 
being particularly marked for strokes (risk 
ratio=1.18; 95% CI, 1.07–1.30). The pri-
mary outcome researchers evaluated was 
a composite of stroke, myocardial infarc-
tion, and death. 
Calcium	channel	blockers	beat	
beta-blockers	in	recent	review
Finally, a more recent systematic review 
found beta blockers to be inferior to cal-
cium channel blockers and renin-angio-
tensin system inhibitors (ACE inhibitors 
or ARBs) for major endpoints of all-cause 
mortality, coronary heart disease, stroke, 
total cardiovascular events, and cardio-
vascular mortality.9 This review found 
beta-blockers had similar outcomes as 
diuretics but were less well tolerated than 
diuretics (RR= 1.80; 95% CI, 1.33–2.42) 
or renin-angiotensin system inhibitors 
(RR=1.41; 1.29–1.54). 
Thirteen trials with 91,561 par-
ticipants, meeting inclusion criteria, 
compared beta-blockers with placebo 
(4 trials; n=23,613), diuretics (5 trials; 
n=18,241), calcium-channel blockers (4 
trials; n=44,825), and renin-angiotensin 
system inhibitors (3 trials; n=10,828). 
Compared with placebo, beta-blockers re-
duced the risk of stroke (RR=0.80; 95% 
CI, 0.66–0.96) with a marginal fall in to-
tal cardiovascular events (RR=0.88; 95% 
CI, 0.79–0.97), but did not affect all-cause 
mortality (RR=0.99, 0.88–1.11), coro-
nary heart disease (RR=0.93, 0.81–1.07), 
or cardiovascular mortality (RR=0.93, 
0.80–1.09). The effect on stroke was 
less than that of calcium-channel block-
ers (RR=1.24, 1.11–1.40) and renin-an-
giotensin system inhibitors (RR=1.30, 
1.11–1.53). The effect on total cardiovas-
cular events was less than that of calcium- 
channel blockers (RR=1.18, 1.08–1.29).
Recommendations	from	others
The Joint National Committee on Hyper-
tension (JNC-7) states that excellent clin-
ical trial data demonstrate that lowering 
blood pressure with beta-blockers (and 
several other drug classes) will reduce the 
complications of hypertension.10 
The European Society of Cardiol-
ogy recommends beta-blockers as the first 
choice for antihypertensive therapy, alone 
or in combination, for patients with previ-
ous myocardial infarction, ischemic heart 
disease, arrhythmias or heart failure, as-
ymptomatic left ventricular dysfunction, 
diabetes, or high risk of coronary disease, 
based on the efficacy of these drugs in 
these patient populations.11 n
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